The neurotensin (NT) receptor, especially neurotensin receptor 1 (NTS1) is described to be overexpressed in a variety of cancer entities [1], e.g., pancreatic ductal adenocarcinoma [2], non-small cell lung cancer [3], breast cancer [4], and prostate cancer [5], whereas it shows only low expression in the tissue from which these tumors arise. Here, NTS is linked to cancer.